280 related articles for article (PubMed ID: 24735016)
1. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
3. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
4. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
[TBL] [Abstract][Full Text] [Related]
5. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC; Villamor N; Ritgen M; Böttcher S; Ghia P; Zehnder JL; Lozanski G; Colomer D; Moreno C; Geuna M; Evans PA; Natkunam Y; Coutre SE; Avery ED; Rassenti LZ; Kipps TJ; Caligaris-Cappio F; Kneba M; Byrd JC; Hallek MJ; Montserrat E; Hillmen P
Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
[TBL] [Abstract][Full Text] [Related]
6. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
7. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
8. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
[TBL] [Abstract][Full Text] [Related]
9. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
[TBL] [Abstract][Full Text] [Related]
10. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
11. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
14. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients.
Garnache Ottou F; Chandesris MO; Lhermitte L; Callens C; Beldjord K; Garrido M; Bedin AS; Brouzes C; Villemant S; Rubio MT; Belanger C; Suarez F; Deau B; Lefrère F; Hermine O; Asnafi V; Varet B; Macintyre E
Br J Haematol; 2014 Jul; 166(1):50-9. PubMed ID: 24661013
[TBL] [Abstract][Full Text] [Related]
16. Is MRD eradication a desirable goal in CLL?
Moreno C; Ritgen M; Rawstron A
Best Pract Res Clin Haematol; 2010 Mar; 23(1):97-107. PubMed ID: 20620974
[TBL] [Abstract][Full Text] [Related]
17. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
19. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.
Peková S; Marková J; Pajer P; Dvorák M; Cetkovský P; Schwarz J
Mol Diagn; 2005; 9(1):23-34. PubMed ID: 16035732
[TBL] [Abstract][Full Text] [Related]
20. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
